Literature DB >> 25048454

The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome.

Arch G Mainous1, Rebecca J Tanner, Mary M Hulihan, Mirna Amaya, Thomas D Coates.   

Abstract

Entities:  

Keywords:  chelation; iron overload; myelodysplastic syndrome

Mesh：

Substances：

Year:  2014        PMID： 25048454      PMCID： PMC4991026          DOI： 10.1111/bjh.13053

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

1.  Elevated serum transferrin saturation and mortality.

Authors:  Arch G Mainous; James M Gill; Peter J Carek
Journal:  Ann Fam Med       Date:  2004 Mar-Apr       Impact factor: 5.166

2.  Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).

Authors:  Christian Rose; Sabine Brechignac; Dominique Vassilief; Laurent Pascal; Aspasia Stamatoullas; Agnes Guerci; Dalila Larbaa; François Dreyfus; Odile Beyne-Rauzy; Marie Pierre Chaury; Lydie Roy; Stephane Cheze; Pierre Morel; Pierre Fenaux
Journal:  Leuk Res       Date:  2010-02-02       Impact factor: 3.156

3.  Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.

Authors:  Anastasios Raptis; Mei Sheng Duh; Si-Tien Wang; Ellison Dial; Ilias Fanourgiakis; Barry Fortner; Carole Paley; Nikita Mody-Patel; Mitra Corral; Jeffrey Scott
Journal:  Transfusion       Date:  2009-08-28       Impact factor: 3.157

4.  Iron overload in children undergoing cancer treatments.

Authors:  Maëlle de Ville de Goyet; Stéphane Moniotte; Annie Robert; Sophie Dupont; Christiane Vermylen; Francis Veyckemans; Bénédicte Brichard
Journal:  Pediatr Blood Cancer       Date:  2013-07-29       Impact factor: 3.167

5.  Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry.

Authors:  Judith Neukirchen; Frank Fox; Andrea Kündgen; Kathrin Nachtkamp; Corinna Strupp; Rainer Haas; Ulrich Germing; Norbert Gattermann
Journal:  Leuk Res       Date:  2012-05-06       Impact factor: 3.156

6.  Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.

Authors:  Michel Delforge; Dominik Selleslag; Yves Beguin; Agnès Triffet; Philippe Mineur; Koen Theunissen; Carlos Graux; Fabienne Trullemans; Dominique Boulet; Koen Van Eygen; Lucien Noens; Steven Van Steenweghen; Jan Lemmens; Pascal Pierre; Randal D'hondt; Augustin Ferrant; Dries Deeren; Ann Van De Velde; Wim Wynendaele; Marc André; Robrecht De Bock; André Efira; Dimitri Breems; Anne Deweweire; Kurt Geldhof; Wim Pluymers; Amanda Harrington; Karen MacDonald; Ivo Abraham; Christophe Ravoet
Journal:  Leuk Res       Date:  2014-02-14       Impact factor: 3.156
  6 in total
  11 in total

1.  Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis.

Authors:  Hailing Liu; Nan Yang; Shan Meng; Yang Zhang; Hui Zhang; Wanggang Zhang
Journal:  Clin Exp Med       Date:  2019-11-11       Impact factor: 3.984

2.  Deferasirox in a refractory anemia after other treatment options: case report and literature review.

Authors:  Palma Manduzio
Journal:  Clin Case Rep       Date:  2015-03-29

3.  High pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation.

Authors:  Soichiro Sakamoto; Hiroshi Kawabata; Junya Kanda; Tatsuki Uchiyama; Chisaki Mizumoto; Toshiyuki Kitano; Tadakazu Kondo; Masakatsu Hishizawa; Naohisa Tomosugi; Akifumi Takaori-Kondo
Journal:  Cancer Med       Date:  2016-12-01       Impact factor: 4.452

Review 4.  Myelodysplastic Syndromes and Iron Chelation Therapy.

Authors:  Emanuele Angelucci; Silvana Anna Maria Urru; Federica Pilo; Alberto Piperno
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-03-01       Impact factor: 2.576

Review 5.  Optimizing Communication and Adherence to Iron Chelation Therapy From Diagnosis to Treatment in Patients With Myelodysplastic Syndromes.

Authors:  Jayshree Shah; Phyllis McKiernan
Journal:  J Adv Pract Oncol       Date:  2016-11-01

6.  Part 3: Myelodysplastic syndromes-Treatment of low-risk patients without the 5q deletion.

Authors:  Elvira Deolinda Rodrigues Pereira Velloso; Silvia Maria Meira Magalhães; Maria de Lourdes Lopes Ferrari Chauffaille; Renata Buzzini; Wanderley Marques Bernardo
Journal:  Hematol Transfus Cell Ther       Date:  2018-07-27

Review 7.  Myelodysplastic syndromes: moving towards personalized management.

Authors:  Eva Hellström-Lindberg; Magnus Tobiasson; Peter Greenberg
Journal:  Haematologica       Date:  2020-05-21       Impact factor: 9.941

8.  Ferritin level changes and erythroid improvement in a group of adult polytransfused patients treated with Deferasirox.

Authors:  Andrada Viorica Parvu; Anca Bojan; Laura Urian; Tunde Torok; Iulia Andrea Zsoldos; Mihaela Iancu
Journal:  Clujul Med       Date:  2018-07-31

Review 9.  Iron Overload in Myelodysplastic Syndromes: Pathophysiology, Consequences, Diagnosis, and Treatment.

Authors:  Lindsey Lyle; Alex Hirose
Journal:  J Adv Pract Oncol       Date:  2018-05-01

Review 10.  Management of the Older Patient with Myelodysplastic Syndrome.

Authors:  Rory M Shallis; Amer M Zeidan
Journal:  Drugs Aging       Date:  2021-08-03       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.